Epidemiological and immunological reasons for pertussis vaccination in adolescents and adults

Respiratory Physiology and Neurobiology

Volumn 187, Issue 1, 2013, Pages 99-103

  Nitsch Osuch, Aneta ^a   Korzeniewski, Krzysztof ^b   Kuchar, Ernest ^c   Zielonka, Tadeusz ^a   zycińska, Katarzyna ^a   Wardyn, Kazimierz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Booster; Immunization program; Prophylaxis; Whooping cough

Indexed keywords

PERTUSSIS VACCINE;

ADOLESCENT; ADULT; AUSTRIA; BELGIUM; BORDETELLA PERTUSSIS; BULGARIA; CZECH REPUBLIC; DRUG EFFICACY; ESTONIA; FINLAND; FRANCE; GERMANY; GROUPS BY AGE; HUMAN; HUNGARY; IMMUNITY; INCIDENCE; LITHUANIA; NETHERLANDS; PERTUSSIS; POLAND; PRIORITY JOURNAL; REVIEW; SWITZERLAND; VACCINATION;

ADOLESCENT; ADULT; HUMANS; IMMUNIZATION, SECONDARY; PERTUSSIS VACCINE; WHOOPING COUGH;

EID: 84877921421     PISSN: 15699048     EISSN: 18781519     Source Type: Journal    
DOI: 10.1016/j.resp.2013.02.007     Document Type: Review

References (50)

1. ACIP - Advisory Committee on Immunization Practices. 2008. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants. MMWR Morbid. Mortal. Wkly. Rep. 57(RR-4), pp. 1-51.
2. ACIP - Advisory Committee on Immunization Practices. 2011. Updated recommendations for use of tetanus toxoid, reduced diphteria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged < 12 months. MMWR Morbid. Mortal. Wkly. Rep 60(41), pp. 1424-1426.
3. Aguas R., Goncalves G., Gomes G. Pertussis: increasing disease as a consequence of reducing transmission. The Lancet Infectious Diseases 2006, 6(2):112-117.
4. Ausiello C.M., Lande R., Urbani F., la Sala A., Stefanelli P., Salmaso S., Mastrantonio P., Cassone A. Cell-mediated immune responses in four-year-old children after primary immunization with a cellular pertussis vaccines. Infection and Immunity 1999, 67(8):4064-4071.
5. Baillleux F., Coudeville L., Kolenc-Saban A., Bevilacqua J., Barreto L., Andre P. Predicted long-term persistence of pertussis antibodies in tetanus, diphtheria and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine 2008, 26(31):3903-3908.
6. Barreto L., Guasparini R., Meekison W., Noya F., Young L., Mills E. Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria and 5-component acellular pertussis vaccine. Vaccine 2007, 25(48):8172-8179.
7. Bisgard K.M., Pascual F.B., Ehresmann K.R., Miller C.A., Cainfrini C., Jennings C.E., Rebman C.A., Gabel C.A., Gabel J., Schauer S.L., Lett S.M. Infant pertussis: who was the souce?. Pediatr. Infect. Dis. 2004, 23(11):985-989.
8. Bonmarin I., Levy B.D., Baron N., Guiso N., Njamkepo E., Caro V., Renacoq Pertussis surveillance in French hospitals: results from 10 year period. Euro Surveillance 2007, 12(1):34-38.
9. Castagnini L.A., Munoz F.M. Clinical characteristics and outcomes of neonatal pertussis: a comparative study. Journal of Pediatrics 2010, 156(3):498-500.
10. CDC - Centers for Disease Control and Prevention. 2005. Pertussis - United States, 2001-2003. Mortal. Morbid. Wkly. Rep. 54(50), pp. 1283-1286.
11. Celentano L.P., Massari M., Paramatti D., Salmaso S., Tozzi A.E., EUVAC-NET Group Resurgence of pertussis in Europe. Pediatric Infectious Disease Journal 2005, 24(9):761-765.
12. Cherry J.D. Historical review of pertussis and the classical vaccine. Journal of Infectious Diseases 1996, 174(Suppl. (3)):S259-S263.
13. Cherry J.D. Epidemic pertussis in 2012 - the resurgence of a vaccine-preventable disease. New England Journal of Medicine 2012, 367(9):785-787.
14. Cohen P., Scadron S.J. The placental transmission of protective antibodies against whooping cough by inoculation of the pregnant mother. JAMA 1943, 121(9):656-662.
15. Cohen P., Schneck H., Dobow E. Prenatal multiple immunization. Journal of Pediatrics 1951, 38(6):696-704.
16. Crawfort N.S., Pebody R. Recent developments in pertussis. Lancet 2006, 367(9526):1926-1936.
17. Deville J.G., Cherry J.D., Christenson P.D. Frequency of unrecognized Bordetella pertussis infections in adults. Clinical Infectious Diseases 1995, 21(3):639-642.
18. Edelman K., He Q., Mäkinen J., Sahlberg A., Haanperä M., Schuerman L., Wolter J., Mertsola J. Immunity to pertussis 5 years after booster immunization during adolescence. Clinical Infectious Diseases 2007, 44(1):1271-1277.
19. ECDC - European Centre for Disease Prevention and Control, 2010. Pertussis surveillance annual report 2010. (avaiable 2.11.2012). http://www.ecdc.europa.eu/en/publications/Publications/pertussis_report_2010_euvacnet.pdf.
20. ECDC - European Centre for Disease Prevention and Control, 2012. Pertussis vaccination overview in European countries. (available 3.11.2012). http://ecdc.europa.eu/en/activities/surveillance/euvac/schedules/Pages/pertussis_schedule.aspx.
21. Forsyth K., Tan T., von Konig C.H., Caro J.J., Plotkin S. Potential strategies to reduce the burden of pertussis. Pediatric Infectious Disease Journal 2005, 24(Suppl. (5)):S69-S74.
22. de Greeff S.C., de Melker H.E., Westerhof A., Schellekens J.F., Mooi F.R., van Boven M. Estimation of household transmission rates of pertussis and the effect of cocooning vaccination strategies on infant pertussis. Epidemiology 2012, 23(6):852-860.
23. Gzyl A., Augustynowicz E., Rabczenko D., Gniadek G., Slusarczyk J. Pertussis in Poland. International Journal of Epidemiology 2004, 33(2):358-365.
24. Halperin B.A., Morris A., Mackinnon-Cameron D., Mutch J., Langley J.M., McNeil S.A., Macdougall D., Halperin S.A. Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clinical Infectious Diseases 2011, 53(9):885-892.
25. Hellwig S.M., van Speil A.B., Schellekens J.F., Mooi F.R., van de Winkel J.G. Immunoglobulin A - mediated protection against Bordetella pertussis infection. Infection and Immunology 2001, 69(8):4846-4850.
26. Hellwig S.M., Rodrigueaz M.E., Berbers G.A., van de Winkel J.G., Mooi F.R. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. Journal of Infectious Diseases 2003, 188(5):738-742.
27. Hewlett E., Edwards K.M. Clinical practice. Pertussis - not just for kids. The New England Journal of Medicine 2005, 352:1215-1222.
28. Higgs R., Higgis S.C., Ross P.J., Mills K.H. Immunity to respiratory pathogen Bordetella pertussis. Mucosal Immunology 2012, 5(5):485-500.
29. Hodder S.L., Cherry J.D., Mortimer E.A., Ford A.B., Gornbein J., Papp K. Antibody responses to Bortedella pertussis antigens and clinical correlations in elderly community residents. Clinical Infectious Diseases 2000, 31(1):7-14.
30. Hope K., Butler M., Massey P., Cashman P., Durrheim D.N., Stephenson J., Worley A. Pertussis vaccination in child health workers: room for improvement in coverage, policy and practice. BMC Pediatrics 2012, 12:98. doi:10.1186/1471-2431-12-98.
31. Kandola K., Lea A., White W., Santos M. A comparison of pertussis rates in the Northwest Territories: pre- and postacelluar pertussis vaccine induction in children and adolescents. Canadian Journal of Infectious Diseases Medical Microbiology 2005, 16(5):271-274.
32. Le T., Cherry J.D., Chang S.J., Knoll M.D., Lee M.L., Barenkamp S., Bernstein D., Edelman R., Edwards K.M., Greenberg D., Keitel W., Treanor J., Ward J.I., APERT Study Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. Journal of Infectious Diseases 2004, 190(3):535-544.
33. Marconi G.P., Ross L.A., Nager A.L. An resurgence in pertussis: epidemiology and trends. Pediatric Emergency Care 2012, 28(3):215-219.
34. Mertsola J., der Meeren O., He Q., Linko-Parvinen A., Ramakrishnan G., Mannermaa L., Soila M., Pulkkinen M., Jacquet J.M. Decennial administration of reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clinical Infectious Diseases 2010, 51(6):656-662.
35. Mooi F., van Loo I., King A. Adaptation of Bortedella pertussis to vaccination: a cause of its re-emergence?. Emerging Infectious Diseases 2001, 7(Suppl. (3)):S526-S528.
36. Muller F.M., Hoppe J.E., Wirsing von Konig C.H. Laboratory diagnosis of pertussis: state of art in 1997. Journal of Clinical Microbiology 1997, 35(10):2435-2443.
37. National Institute of Public Health-National Institute of Hygiene (NIPH-NIH), 2010. Infectious diseases and poisonings in Poland in 2010. Chief Sanitary Inspectorate - Department for Communicable Disease and Infection Prevention and Control. (avaiable 12.11.2012). http://www.pzh.gov.pl/oldpage/epimeld/2010/Ch_2010.pdf.
38. Paterson J.M., Sheppeard V. Nosocomial pertussis infection of infants: still a risk in 2009. Communicable Diseases Intelligence 2010, 34(4):440-443.
39. Purdy K.W., Hay J.W., Botteman M.F., Ward J.I. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clinical Infectious Diseases 2004, 39(1):20-28.
40. Raya B.A., Bamberger E., Spiegel G., Sprecher H., Davidson S., Geffen Y., Srugo I. Two closely related strains associated with pertussis resurgence in Israel. Pediatric Infectious Disease Journal 2012, 31(7):761-762.
41. Rieber N., Graf A., Hartl D., Urschel S., Belohradsky B., Liese J. Acellular pertussis booster in adolescents induces Th1 and memory CD8+ T cell immune response. PLos ONE 2011, 6(3):e17271. 10.1371/journal.pone.0017271.
42. Ryan M., Murphy G., Ryan E., Nilsson L., Shackley F., Gothefors L., Oymar K., Miller E., Storsaeter J., Mills K.H. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 1998, 93(1):1-10.
43. Schure R., de Rond L., Ozturk K., Hendrikx L., Sanders E., Berbers G., Buisman A.M. Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age. PLos One 2012, 7(7):e41928. 10.1371/journal.pone.0041928.
44. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998, 16(20):1907-1916.
45. Vermeulen F., Verscheure V., Damis E., Vermeylen D., Leloux G., Dirix V., Locht C., Mascart F. Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines. Clinical Vaccine Immunology 2010, 17(2):258-262.
46. Wearing, H.J., Rohani, P., 2009. Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathology 5 (10), e1000647. Available at: http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.
47. Wendelboe A.M., Van Rie A., Salmaso S., Englund J.A. Duration of immunity against pertussis after natural infection or vaccination. Pediatric Infectious Disease Journal 2005, 24(Suppl. 5):S58-S61.
48. WHO, 2010. Report Summary of the WHO position paper on pertussis vaccines, 1 October 2010. Available at: (avaiable 28.10.2012). http://www.who.int/immunization/Pertussis_position_paper_summary_oct2010.pdf.
49. Wood N., McIntyre P. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatric Respiratory Reviews 2008, 9(3):201-211.
50. Zepp F., Heininger U., Mersola J., Bernatowska E., Guiso N., Roord J., Tozzi A.E., Van Damme P. Rationale for pertussis booster vaccination through life in Europe. Lancet Infectious Diseases 2011, 11(7):557-570. 10.1016/S1473-3099(11)70007-X.